P&G closes diagnostics deal
This article was originally published in The Tan Sheet
Executive Summary
Procter & Gamble and Inverness Medical Innovations complete a previously announced deal to create SPD Swiss Precision Diagnostics, a 50/50 joint venture business that develops, manufactures and markets diagnostic products, the firms announce May 17. The new company is headquartered in Geneva and will be the world's leading provider of home pregnancy test and fertility/ovulation monitoring products with brands including Clearblue and Fact Plus, say the firms, which outlined plans for the partnership in January (1"The Tan Sheet" Jan. 1, 2007, p. 10)...
You may also be interested in...
P&G Moves Into Consumer Diagnostics With Inverness Joint Venture
Procter & Gamble enters the consumer diagnostic products business with an agreement to form a 50/50 joint venture with Waltham, Mass.-based Inverness Medical Innovations
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.